Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS

Next Previous
Trial Profile

AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF ARV-471 (PF-07850327) ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Vepdegestrant (Primary)
  • Indications Cardiomyopathies; Cardiovascular disorders; Deep vein thrombosis; Embolism; Gastrointestinal haemorrhage; HER2 negative breast cancer; Pulmonary embolism; Stroke; Vascular disorders; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 29 Mar 2024 Results evaluating the impact of vepdegestrant on the PK of dabigatran etexilate (a model substrate for P glycoprotein in healthy adults , presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 19 May 2023 Status changed from active, no longer recruiting to completed.
  • 25 Mar 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top